
MSCI Completes Acquisition of Trove Research
MSCI Inc. (NYSE: MSCI), a leading provider of mission-critical decision support tools and services for the global investment community, today announced that it has completed its acquisition of Trove Research, a firm specializing in data and analytics on the voluntary carbon markets.
The acquisition was originally announced on October 10, 2023.
Henry Fernandez, Chairman and Chief Executive Officer, MSCI, said: “The completion of this acquisition represents a milestone for MSCI. Trove’s data and analytics will help us develop a wide range of solutions for the voluntary carbon market, which is critical to supporting our clients as they manage carbon emissions in their portfolios. Through these solutions, MSCI will promote greater clarity and consistency for investors and companies across industries.”
About MSCI Inc.
MSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, we power better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. We create industry-leading research-enhanced solutions that clients use to gain insight into and improve transparency across the investment process. To learn more, please visit www.msci.com. MSCI#IR
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements relating to the integration of Trove Research and prospects for the newly acquired business. These forward-looking statements relate to future events or to future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond MSCI’s control and that could materially affect actual results, levels of activity, performance or achievements.
Other factors that could materially affect actual results, levels of activity, performance or achievements can be found in MSCI’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the Securities and Exchange Commission (“SEC”) on February 10, 2023 and in quarterly reports on Form 10-Q and current reports on Form 8-K filed or furnished with the SEC. If any of these risks or uncertainties materialize, or if MSCI’s underlying assumptions prove to be incorrect, actual results may vary significantly from what MSCI projected. Any forward-looking statement in this press release reflects MSCI’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MSCI’s operations, results of operations, growth strategy and liquidity. MSCI assumes no obligation to publicly update or revise these forward-looking statements for any reason, whether as a result of new information, future events, or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231101965032/en/
Contact information
Investor Inquiries
jeremy.ulan@msci.com
Jeremy Ulan +1 646 778 4184
jisoo.suh@msci.com
Jisoo Suh +1 917 825 7111
Media Inquiries
PR@msci.com
Melanie Blanco +1 212 981 1049
Konstantinos Makrygiannis +44 (0) 7768 930056
Tina Tan +852 2844 9320
MSCI Global Client Services
EMEA Client Service + 44 20 7618.2222
Americas Client Service +1 888 588 4567 (toll free)
Asia Pacific Client Service + 852 2844 9333
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VIOOH Shares Industry-first Carbon Emissions Measurement Hitting 18% Below Benchmark11.12.2023 09:00:00 CET | Press release
Today, VIOOH, the leading premium global digital out of (DOOH) home supply-side platform, announced a partnership with the Carbon Intelligence Platform, Cedara, a supporter of Ad Net Zero. In an industry first for a programmatic DOOH (prDOOH) player, VIOOH has shared publicly its impression intensity carbon emissions (grams CO2e) per ad impression for 2022, which is 18% below the programmatic open web benchmark. Based on Cedara’s measurement, VIOOH generated 0.28 grams CO2e per ad impression in 2022, well below the Cedara ad platform benchmark of 0.34, which is based on programmatic open web vendor data. VIOOH worked closely with Cedara on a comprehensive greenhouse gas (GHG) inventory assessment across its operations, including programmatic media activity, which contributes the majority of Scope 3 emissions. As part of its measurement process, Cedara not only analysed data sets from business operations, but also activity data from media delivery, data centres, and media owners, amongs
Hexadrone Starts C5 and C6 Drone Type Examination After Successful GAP Analysis of The TUNDRA 2’ Specification by Notified Body11.12.2023 08:30:00 CET | Press release
Hexadrone SAS, A French Modular UAV’s Manufacturer Created in 2014 has successfully completed GAP Analysis for The Tundra 2 in its Urban and Endurance versions versus DR EU 2019/945 with intension for Class Identification Label C5 and C6. With the achievement of this milestone, the certification process for both Urban and Endurance Version have been now formally triggered by Hexadrone to be performed by the notified body NavCert GmbH. The Tundra 2 is bringing on the market a key differentiator by providing extreme modularity on UAVs, integrating unlimited type of payloads used in various sectors like, Surveillance, Geospatial, Agriculture, Oil and gas, Military, Homeland security, Rescue and much more. “Through an in-depth analysis based on European Union (EU) Regulation 2019/945, we have ensured that the specifications of the Tundra 2 as well as our user manuals fully meet the current requirements. This compliance will ensure that the TUNDRA 2 users will be able to fly in European air
VINSSEN Co., Ltd. Successfully Supplies Hydrogen Fuel Cell for Industry Project in Singapore11.12.2023 08:00:00 CET | Press release
VINSSEN Co., Ltd. (CEO Chil-Han Lee), a company specializing in the production of electric and hydrogen hybrid propulsion systems, has successfully tested and delivered a hydrogen fuel cell system for a trial project involving several key industry partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210481971/en/ Hydrogen fuel cell power generation equipment is undergoing inspection before delivery (Photo: VINSSEN Co., Ltd.) VINSSEN is collaborating with Shell Singapore Pte. Ltd. (Shell) as the project sponsor, Seatrium Limited as the project developer, Penguin International Limited as the owner and operator of the vessel, and Air Liquide Singapore Private Limited as the hydrogen supplier. This project is a pilot to test the use of hydrogen fuel cells in maritime applications, marking the first step in confirming feasibility of hydrogen as a marine fuel. The hydrogen fuel cell system has been delivered from Korea and
New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation11.12.2023 08:00:00 CET | Press release
Masimo (NASDAQ: MASI) today announced the findings of a retrospective study published in the Journal of Anesthesia in which Dr. Yu Jeong Bang and colleagues at the Samsung Medical Center, Sungkyunkwan University School of Medicine, in Seoul, South Korea, investigated the association of Masimo ORi™ and the arterial partial pressure of oxygen (PaO2) in 554 patients who underwent non-cardiac thoracic surgery during one-lung ventilation (OLV), making this study the largest to date on ORi. The researchers found that ORi values “were significantly correlated with PaO2 measured simultaneously” and that ORi “could provide useful information on arterial oxygenation even during one-lung ventilation.”1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210873994/en/ Masimo Root® with ORi™ (Photo: Business Wire) Noninvasive, continuous Masimo ORi provides continuous, real-time insight into the oxygenation of hemoglobin in the moderate hy
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement11.12.2023 07:00:00 CET | Press release
Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210383233/en/ The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration. The financial details of this deal are undisclosed. “This agreement is the latest in Ferring’s long term mission to maximise the therapeutic potential of the gut microbiome for the benefit of patients. PharmaBiome’s unique technology enables identification and manufacturing of defined consortium live microbiome biotherapeutics that could reverse microbiome dysbiosis linked to disease,” said Carl Bilbo, Senior Vice President, Micr